TASK DEFINITION: Given a document and an entity the task is to select the author's sentiment towards the entity. Sentiments can be Positive, Neutral and Negative. Select Positive if the article expresses a positive view towards the given entity or praises its quality or skills. Select Neutral if the document expresses no clear view towards the entity or has equal amounts of positive and negative statements or expressing some fact/quote by someone else. Select Negative if the article expresses a negative view towards like harsh remarks, criticizing entities action/decision etc. Note that URLs in the text have been replaced with [Link].
PROBLEM: What is the sentiment of the following document towards the entity Mousa Dembele ? London (AFP) â Kevin De Bruyne was the creative fulcrum of Manchester Cityâs latest demolition job  while Mousa Dembele inspired Tottenhamâs north London derby triumph.
 Dembele  the midfield maestro
 Mousa Dembele  underlined  his  status as one of Tottenhamâs unsung heroes with a dominant display in their 1-0 win over north London rivals Arsenal. It was Harry Kaneâs latest goal-scoring exploits against the Gunners that took centre-stage at Wembley  but the platform of that success was built by  the industrious Dembele . Embodying Mauricio Pochettinoâs obsession with physical intensity  while more than capable of picking a decisive pass  Dembele out-shone Arsenal in the midfield engine room  earning praise from  his  manager. âLast season  he  played so well  this season  he  suffered a problem in  his  ankle and struggled in pre-season. Now  he  is playing well again â Pochettino said. â He  is an unbelievable player. We have to be careful about  his  fitness. When  he  can train  he  can make this type of performance.â
As if losing 1-0 to struggling Newcastle wasnât enough to have Jose Mourinho seething  the Manchester United boss once again had to suffer the frustration of  Paul  Pogbaâs latest flop. Mourinho had restored Pogba to the starting line-up after dropping him for Unitedâs previous match â a decision inspired by the former Juventus midfielderâs limp efforts in a defeat at Tottenham. But rather than grasp the opportunity to get back in Mourinhoâs good books just days after his boss had defended their relationship  Pogba was again a largely anonymous figure at St Jamesâ Park. By the time he was substituted midway through the second half  United were already trailing  but publicly at least  Mourinho remains supportive. âNo problems â he said when asked about the France international. âI wanted a better way (in midfield) against a side that was defending in a block. I wanted the simplicity of Michael Carrick.â

SOLUTION: Positive

PROBLEM: What is the sentiment of the following document towards the entity Deborah Danner ? City EMT Patrick Moore said he was prepared to move emotionally disturbed  Deborah Danner  safely out of  her  Bronx apartment â and then the shooting started.
An angry  Danner   66  had stopped screaming as Moore went to grab a chair used to move patients. A half-dozen police officers simultaneously entered  her  bedroom on Oct. 18  2016  the first responder testified Friday.
âI assumed they were going to restrain  her  â said Moore under questioning from Bronx prosecutor Newton Mendys in the murder trial of NYPD Sgt. Hugh Barry.
Instead  Moore recounted  he heard cops shouting at the heavy-set older woman to âput it down  get downâ â apparently a reference to a baseball bat that  Danner  was holding.
 Deborah Danner  asked to be left alone before fatal NYPD shooting
 Deborah Danner  (Facebook)
Moore recounted that the EMTs could hear  Danner  screaming when they reached the seventh floor of the building. When they reached  her  apartment   Danner  was holding a pair of scissors in  her  hands.
Front page of New York Daily News for June 1 shows Barry charged with  Danner 's murder. (New York Daily News)
Within a short time   Danner  was conducting a âfairly normal conversation with Brittney â Moore testified  adding that he kept his distance from the patient to avoid upsetting  her  âin any way.â
Barryâs lawyer has argued the sergeant was forced to make a split-second life or death decision when  Danner  grabbed the baseball bat.
â Mrs. Danner  was the aggressor and  she  was about to kill my client â said defense attorney Andrew Quinn.

SOLUTION: Positive

PROBLEM: What is the sentiment of the following document towards the entity Kymriah ? The drug  called  Kymriah   is a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor).
The FDA approved  Kymriah  to treat pediatric acute lymphoblastic leukemia in people up to age 25.
The one-time treatment isn't cheap: Novartis  which makes  Kymriah   on Wednesday said the price would be $475 000  which is lower than many expected. Only about 600 people a year could get this treatment  based on Wednesday's approval. Even so  the approval has industry experts and cancer doctors excited.
How  Kymriah  works
 Kymriah  isn't your run-of-the-mill pill â or even a biologic drug  like insulin â that can be mass produced. Since the therapy is made from a person's own immune system  the process can take about three weeks.
While that's a one-time process  it's not the end of the road. About half of the patients in a Kymriah study got cytokine-release syndrome  a response to the reprogrammed cells running loose in the body. It can cause high fevers and flu-like symptoms  and it can be life-threatening. If they get it  patients need to be admitted to intensive-care units  which can bring additional costs. (The FDA on Wednesday expanded the approval of Actemra  a rheumatoid-arthritis drug that can also treat cytokine-release syndrome.)
In a trial of 63 patients treated with Kymriah  83% were in remission after three months  and 64% were still in remission after a year.
Kymriah is the first CAR-T cell therapy to get approved  and several more are in the works. Kite Pharma  Juno Therapeutics  and Bluebird Bio are among a growing group of biotech companies working with CAR-T. Kite  which was recently acquired by Gilead Sciences  is expected to hear back from the FDA about its treatment for aggressive B-cell non-Hodgkin lymphoma by November.
"We're at the very beginning of what's going to be a big new field of medicine " said  David Epstein  who helped license Kymriah from the University of Pennsylvania while at Novartis .
 Epstein  left Novartis in 2016 as CEO of its pharmaceuticals divisions.  He 's now the executive chairman of Rubius Therapeutics  a biotech firm that's also working with cell therapy to develop treatments like  Kymriah  that don't have to be as personalized. The hope is that one day doctors will be able to prescribe a cell therapy and use it that same day instead of waiting weeks to get it back.
 Epstein  said  he  envisioned cell therapies having much shorter life cycles than traditional drugs. Instead of getting a better  updated therapy for a disease every decade or so  we might begin to see second-generation cell therapies in a few years.
Those updates could increase the number of patients that cell therapies can treat. The 600 or so people a year eligible for  Kymriah  now could become tens of thousands  but  it  would require some major changes   Epstein  said.
For one  the treatments would have to treat more types of cancer than the one  Kymriah  was approved for on Wednesday.
And to affect more people  the cell therapies would need to go beyond blood cancers. Right now  that's where most of the big successes have come from  but that could one day include solid tumors and maybe even autoimmune diseases like Type 1 diabetes   Epstein  said.

SOLUTION:
Positive